Alithea Genomics SA

Based in Epalinges, Switzerland, and founded in 2020, Alithea Genomics SA operates as a biotechnology company providing transcriptomics and RNA sequencing solutions for drug discovery, biomarker research, and other life sciences applications. The company was co-founded by Daniel Alpern and Riccardo Dainese. As of October 2026, Frederik Decouttere serves as Chief Executive Officer of the company. In March 2026, Alithea Genomics SA raised CHF 3 million in seed funding led by Genku Ventures, with participation from Zurcher Kantonalbank, Novalis Biotech.

The round was part of a larger CHF 6. 8 million seed funding. Alithea Genomics SA provides scalable RNA sequencing products and services based on its MERCURIUS™ BRB-seq technology, enabling high-throughput and cost-effective transcriptome and gene-expression profiling. The company offers BRB-seq library preparation kits for purified RNA, blood RNA and cell lysates, as well as RNA sequencing services for industrial and academic research applications.

The company generates revenue through the sale of RNA sequencing and library preparation kits, as well as through the provision of RNA sequencing and transcriptomics services to industrial and academic customers. The company plans to use the February 2026 funding to expand MERCURIUS™ DRUG-seq kit commercialization, develop new technologies, and grow transcriptomic data for AI and machine learning.